---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-042176"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2026-06-10T20:05:24+00:00"
generated_at: "2026-06-10T20:12:12.778571+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Bicara Therapeutics stockholders elect directors and ratify KPMG as auditor

## Summary
- Elected Dr. Christopher Bowden and Dr. Carolyn Ng as Class II directors for three-year terms.
- Bowden: 48,558,710 for, 5,145,418 withheld; Ng: 47,431,269 for, 6,272,859 withheld.
- Ratified KPMG LLP as independent auditor for FY2026: 55,914,602 for, 8,815 against, 1,570 abstain.
- 85.25% of outstanding shares (55.9M of 65.6M) were present or represented at the meeting.

## SEC filing metadata
- accession: 0001628280-26-042176
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2026-06-10T20:05:24+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000162828026042176/0001628280-26-042176-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000162828026042176/bcax-20260609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-042176
- JSON: https://secwatch.observer/filing/0001628280-26-042176.json
- Plain text: https://secwatch.observer/filing/0001628280-26-042176.txt

## Key facts
- Shareholder Votes
  Bicara Therapeutics Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-06-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 2: Ratification of KPMG LLP The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Votes Abstaining Ratification of appointment of KPMG LLP 55,914,602 8,815 1,570
  evidence_url: https://www.sec.gov/Archives/edgar/data/2023658/000162828026042176/0001628280-26-042176-index.htm
- Shareholder Votes
  Bicara Therapeutics Inc. shareholders approved Election of Class II Directors at the 2026-06-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: Proposal 1: Election of Directors The Company's stockholders elected each of the following individuals to serve as class II directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows: Director Votes For Votes Withheld Broker Non-Votes Christopher Bowden, M.D. 48,558,710 5,145,418 2,220,859 Carolyn Ng, Ph.D. 47,431,269 6,272,859 2,220,859
  evidence_url: https://www.sec.gov/Archives/edgar/data/2023658/000162828026042176/0001628280-26-042176-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.